Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24321953 | 0.96 | SLC29A1 (0.38) | SLC29A1P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL25688757 | 0.86 | SLC29A1 (0.36) | SLC29A1P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL24321888 | 0.85 | SLC29A1 (0.34) | SLC29A1P2RY12 | |
| SCHEMBL25688777 | 0.83 | SLC29A1 (0.36) | SLC29A1P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL25688747 | 0.81 | TYMP (0.32) | SLC29A1 | |
| SCHEMBL25688776 | 0.77 | TYMP (0.32) | SLC29A1 | |
| SCHEMBL18490426 | 0.74 | KDM4E (0.47) | P2RY12ADORA1 | |
| SCHEMBL25688735 | 0.73 | TYMP (0.32) | SLC29A1 | |
| SCHEMBL20547957 | 0.73 | P2RY12 (0.33) | P2RY12ADORA1 | |
| SCHEMBL21263831 | 0.73 | SLC29A1 (0.34) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | SLC29A1 367/4885P2RY12 1351/4885ADORA1 1492/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | SLC29A1 367/4885P2RY12 1351/4885ADORA1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.